{
    "nct_id": "NCT06255782",
    "official_title": "A Phase I/II First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of a Single Intravenous (IV) Administration of ECUR-506 in Males Less Than 9 Months of Age With Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency",
    "inclusion_criteria": "1. Male sex\n2. Gestational age ≥ 37 weeks\n3. Age at screening is 24 hours to 7 months*\n4. Weight ≥ 3.5 kg and ≤ 10.0 at screening\n5. Has received all age-appropriate vaccinations\n6. Genetically confirmed OTCD\n7. Severe neonatal OTCD defined by hyperammonemic crisis within first week of life\n8. Current or historical biochemical profile consistent with OTCD\n9. Participant's parent(s)/LAR must be able to comprehend and be willing to provide a signed IRB/IEC-approved ICF.\n\nKey\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 24 Hours\nMust have maximum age of 7 Months",
    "exclusion_criteria": "1. Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to birth injury\n2. Requiring urgent liver transplant due to liver failure as assessed by the PI.\n3. Contiguous gene deletion involving the OTC gene\n4. Known or suspected major organ injury/dysfunction/anomalies.\n5. Treatment with any other gene therapy or gene editing therapy\n6. Co-enrollment in any other clinical study with an investigational product prior to or during the duration of this trial would require the participant to be withdrawn from this study\n7. Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data\n8. Documented vertical transmission of HSV, HIV, or HepA/HepB/HepC\n9. Documented in-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant's risk of developmental delays, congenital anomalies, and/or significant medical complications",
    "miscellaneous_criteria": "Key"
}